Online:
Visits:
Stories:
Profile image
By ProactiveInvestors (Reporter)
Contributor profile | More stories
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

M Pharma to target untapped area of the female sexual dysfunction market

Thursday, January 12, 2017 7:33
% of readers think this story is Fact. Add your two cents.

(Before It's News)

M Pharmaceutical Inc (CNSX:MQ) is to develop a drug product aimed at women who find it difficult to become sexually aroused.

The company, best known for its development of treatments for obesity and weight management, is broadening its portfolio following the proposed acquisition, announced earlier this month, of Cincinatti-based 40Js.

As part of its planned acquisition, M Pharma will continue to advance the development of a patented topical drug product for the treatment of female sexual dysfunction (FSD).

“Unlike the other two drugs approved by the US Food and Drug Administration [FDA] to treat FSD, our topical drug product would focus on women with orgasm and arousal difficulties,” said Gary Thompson, chief executive officer of M Pharmaceutical USA.

“Valeant’s Addyi, recently acquired from Sprout Pharmaceuticals, is indicated only for HSDD (desire disorder) with a number of FDA-imposed prescription and marketing restrictions,” Thompson noted.

“Intrarosa, by Endoceutics, is indicated for dyspareunia (pain with intercourse) with certain prescribing restrictions. Our proposed treatment is topical, local and non-systemic, with daily and on-demand use, while being non-hormonal and not a central nervous system drug,” he added.

Based on the core attributes of its treatment, the safety profiles of the active and inactive pharmaceutical ingredients, the dosage and delivery form, M Pharma expects the product will be extremely well tolerated and highly effective for a large number of women suffering from FSD.

If Thompson’s prediction is correct, then it should have a very good chance of being approved by the FDA.

Story by ProactiveInvestors



Source: http://www.proactiveinvestors.com/companies/news/171551/m-pharma-to-target-untapped-area-of-the-female-sexual-dysfunction-market-171551.html

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.